NCT05457738

Brief Summary

The main characteristic of PAD is to limit physical activity by the appearance of claudication of the lower limbs which limits the walking distance, or the maximum distance traveled by the patient before the pain forces to stop. In daily practice, the walking distance is rarely measured at the time of treatment. Walking rehabilitation is the first-line treatment for these patients (class 1 recommendation from the AHA 2005 and the ESC 2017 with level A evidence). According to the recommendation, a walking session must last at least 30 minutes at the rate of 3 sessions per week for a minimum of 6 months. Walking rehabilitation should be systematically offered to all claudicating patients, whether operated on or not. It is often sufficient for mild claudication with a walking distance of more than 500 meters. Surgery should be reserved for patients in whom rehabilitation has failed and in whom the claudication is severe (walking distance less than 500 meters). Surgical intervention should not replace rehabilitation, but should be complementary. Supervised rehabilitation in specialized centers is rarely offered because it is not easily available and involves additional expenses and constraints for the patient (transport, fewer work periods for active patients, etc.). In the absence of specialized center, simple advice is most often given to the patient, who then only has to rely on his personal motivation: this is the so-called "go home and walk". Therefore, access to well-conducted rehabilitation is a fundamental element of the management of patients with intermittent claudication, which is currently lacking. In the age of digital health, it is necessary to develop innovative tools allowing self-rehabilitation of the patient in addition with remote monitoring by the doctor. Recent studies have validated and highlighted the interest of using GPS technology for the evaluation of walking activity in claudicants. To date, there are 2 published examples of smartphone applications developed specifically for exercise rehabilitation. The main shortcomings of the solutions proposed in these publications are:

  • The need to buy a specific GPS box
  • Discomfort for the patient to carry the box either in a backpack or over the shoulder
  • The lack of means for the patient to indicate the precise moment when the pain appears
  • And consequently the absence of clinical analysis centered on the symptom "walk induced pain" Consumer smartphone applications for GPS activity tracking are not intended for medical use and do not indicate when pain occurs. In this study, the University Hospital of REIMS will establish a scientific collaboration with the company VascInnove® for the use of a smartphone application, called E-REVA® which offers:
  • an assessment of walking activity and claudication parameters (appearance of pain, walking distance, recovery time after pain, total distance travelled, walking speed, etc.)
  • help with self-rehabilitation
  • quality of life and walking questionnaires The main innovation is the presence of a button allowing the patient to indicate when the pain appears. The patient will be able to have access via the smartphone application to his statistics and the evolution of his performance over time. The prescribing practitioner will have access, via a secure website, to the statistics of his patient, to whom he will be able to give personalized advice during follow-up consultations. The aim of this study is to carry out a single-centre prospective randomized stratified study (depending on whether or not patient has been revascularized) in patients with intermittent claudication who will or will not use the rehabilitation assistance smartphone application, seen in consultation for vascular surgery and vascular medicine at the University Hospital of Reims.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for not_applicable

Timeline
25mo left

Started Apr 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress50%
Apr 2024May 2028

First Submitted

Initial submission to the registry

June 30, 2022

Completed
14 days until next milestone

First Posted

Study publicly available on registry

July 14, 2022

Completed
1.8 years until next milestone

Study Start

First participant enrolled

April 19, 2024

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 19, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 19, 2028

Last Updated

January 20, 2025

Status Verified

January 1, 2025

Enrollment Period

4.1 years

First QC Date

June 30, 2022

Last Update Submit

January 17, 2025

Conditions

Keywords

Intermittent claudicationperipheral arterial diseasesupervised exercise therapyhome-based exercisesmartphone medical application

Outcome Measures

Primary Outcomes (2)

  • maximal walking distance on treadmill test

    3 months

  • maximal walking distance on treadmill test

    12 months

Secondary Outcomes (2)

  • Quality of life assessment VascuQol-6

    6 months

  • Walking Impairment Questionnaire

    6 months

Study Arms (2)

patients randomized to using the smartphone app

EXPERIMENTAL
Other: E-REVA® app

patients randomized to not using the smartphone app

ACTIVE COMPARATOR
Other: No E-REVA® app

Interventions

Use of a smartphone app designed for home-based exercise therapy of patients with intermittent claudication. App's name is E-REVA®.

patients randomized to using the smartphone app

No use smartphone

patients randomized to not using the smartphone app

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • \- Patient over 18 years old
  • Patient with claudication on PAD for more than 3 months
  • IPS (systolic pressure index) less than 0.90 at the level of the diseased limb
  • Absence of pathology limiting walk other than PAD
  • Patient having benefited from an arterial ultrasound of the lower limbs demonstrating arterial lesion
  • Absence of myocardial infarction over the last 6 months
  • Absence of cardiac pathology requiring surgery
  • Absence of angina
  • Patient affiliated or entitled to a social security system
  • Patient having given his free and written consent

You may not qualify if:

  • Patient who has not benefited from an arterial ultrasound of the lower limbs
  • All contraindications to treadmill events:
  • Myocardial infarction within the last 6 months
  • angina
  • Symptomatic tight aortic valve stenosis
  • Pathology limiting walk other than PAD

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Damien JOLLY

Reims, France

RECRUITING

MeSH Terms

Conditions

Intermittent ClaudicationPeripheral Arterial Disease

Condition Hierarchy (Ancestors)

Peripheral Vascular DiseasesVascular DiseasesCardiovascular DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsAtherosclerosisArteriosclerosisArterial Occlusive Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 30, 2022

First Posted

July 14, 2022

Study Start

April 19, 2024

Primary Completion (Estimated)

May 19, 2028

Study Completion (Estimated)

May 19, 2028

Last Updated

January 20, 2025

Record last verified: 2025-01

Locations